Micro-Tech Endoscopy’s acquisition of global distribution rights for key Conmed GI products isn’t just a portfolio expansion—it’s a strategic consolidation of control across the endoscopy value chain. By bringing Duraclip (hemostasis) and Precisor/Optibite (biopsy) fully in-house, Micro-Tech is moving from being a behind-the-scenes manufacturer to a frontline commercial player with a more complete procedural toolkit. The timing is equally telling. Conmed’s exit from the GI segment reflects a broader reality in medtech: fragmented portfolios are giving way to focused, category-dominant players. In contrast, Micro-Tech is doubling down—building an integrated offering that spans closure, biopsy, and visualization. For providers, especially ASCs,…
Author: Abhay Panchal
Olympus’ $1M+ equipment grant to ASGE isn’t just philanthropy—it’s a strategic investment in shaping the next generation of endoscopists and, indirectly, the future of procedural adoption. By equipping ASGE’s training institute with its latest EVIS X1 systems, Olympus is embedding its technology directly into the learning environment of fellows and practicing GIs—where preferences, habits, and platform familiarity are formed early. This highlights a deeper dynamic in GI: as endoscopy becomes more advanced (ERCP, EUS, ESD), the bottleneck is no longer just technology—it’s training, proficiency, and comfort with increasingly sophisticated systems.
A new liquid biopsy platform, cf-EpiTracing, is pushing non-invasive diagnostics beyond detection—into understanding where disease actually comes from. Developed by researchers at Peking University, the technology can extract detailed epigenetic signals from just a drop of blood, enabling tissue-of-origin tracing, disease subtyping, and outcome prediction—a long-standing limitation of traditional liquid biopsies. In colorectal cancer, early results show striking accuracy (over 90% in validation cohorts), pointing toward a future where screening could move upstream—earlier, simpler, and potentially more precise than today’s methods. But the bigger shift is conceptual. Liquid biopsies are evolving from binary “signal detection” tools into multi-dimensional diagnostic platforms,…
The American College of Gastroenterology’s first comprehensive guideline on hepatic encephalopathy (HE) marks a notable shift: from clinician-driven protocols to patient-centered, real-world management of a complex, often underdiagnosed condition. Led by Dr. Jasmohan Bajaj, the guidance challenges long-held clinical habits—most notably the overreliance on ammonia levels—arguing instead for symptom-driven assessment and practical cognitive testing that can actually be implemented in routine care. But the deeper change is philosophical. HE is no longer framed purely as a hepatic complication—it’s positioned as a multidimensional disease affecting cognition, caregivers, and quality of life, requiring involvement beyond the physician.
Walgreens is taking colorectal cancer screening out of the clinic and into retail—partnering with Exact Sciences to offer Cologuard access directly through its nationwide pharmacy footprint. At first glance, this looks like a convenience play. But the deeper shift is structural: screening is being embedded into everyday healthcare touchpoints, targeting the persistent gap where over one-third of eligible adults remain unscreened. By integrating clinical workflows into pharmacy operations, Walgreens is turning pharmacists into activation points for preventive care—bridging awareness and action in a way traditional healthcare settings often fail to do. The model also reflects a broader trend: decentralizing screening…
Digbi Health is positioning itself at the center of a structural shift in obesity care—where rising GLP-1 demand is forcing employers to rethink traditional pharmacy benefit models. With the launch of Digbi RxFund™ and the expansion of its GLP-1 Compass platform, the company is introducing a hybrid financial + clinical model that moves away from opaque, all-or-nothing PBM coverage toward flexible, employer-controlled funding pathways. But the real differentiation lies beyond financing. Digbi is attempting to manage the entire GLP-1 lifecycle—from prevention and patient selection to tolerability and long-term dependency—using a combination of genetics, gut microbiome insights, and metabolic data. This…
Endo Tools Therapeutics has secured FDA 510(k) clearance for its next-generation endomina® EZFuse system—marking a meaningful step in the evolution of endoscopic suturing from technically demanding procedures toward streamlined, scalable workflows. The core shift isn’t just incremental device improvement—it’s operational. By enabling up to 50% reduction in procedure time through a simplified, single-movement suturing mechanism, EZFuse directly targets one of endoscopy’s biggest bottlenecks: time, complexity, and staff burden.This positions endoscopic suturing not just as a clinical capability, but as a throughput and efficiency lever for GI practices and ASCs—unlocking higher case volumes, improved scheduling flexibility, and reduced procedural fatigue.
In the Through the Scope video series, Rajesh Keswani from Northwestern University Feinberg School of Medicine demonstrates the resection of a rectal carcinoid tumor. He explains that carcinoid tumors often arise deep in the mucosa, making them difficult to remove using conventional endoscopic mucosal resection (EMR). Instead, endoscopic full-thickness resection can provide a safe and effective technique to remove these lesions while achieving clearer and deeper margins.
Researchers from National Taiwan University developed PanMETAI, an AI-powered diagnostic platform that detects early-stage pancreatic cancer using a small blood sample. The system combines AI with NMR metabolomics to analyze metabolic fingerprints in the blood. In testing, the platform achieved up to 94% diagnostic accuracy and showed strong performance across international patient groups. By analyzing metabolic signals alongside biomarkers like CA19-9 and Activin A, the model can identify subtle metabolic changes linked to early cancer.
A report from Vizient describes 2026 as a “reset” year for U.S. healthcare, driven by rising patient complexity, workforce shortages, and rapid adoption of AI. Physicians are seeing older, sicker patients with more comorbidities, while hospitals and practices continue to face thin margins, rising costs, and staffing shortages. Key trends shaping the industry include: Experts say practices that focus on improving patient access, adopting digital tools, and building team-based care models will be best positioned to remain financially viable.